BioAdvance - Articles
Newsroom >> BioAdvance and Regional News

Today’s Top Regional Life Sciences Stories from Business Wire

Derma Sciences Novel XTRASORB® HCS Dressings Receive Federal Reimbursement Codes; Join Foam and Classic Dressings for Complete Coverage of Product Category
PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces that all five products in its novel line of XTRASORB® HCS Dressings have received Healthcare Common Procedural Coding System (HCPCS) codes. These codes – A6234 through A6238 – were awarded by the Centers for Medicare and Medicaid Services (CMS), and allow healthcare providers to bill for the dressings beginning immediately. XTRASORB HCS make
CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--CRF Health completed the ePRO vendor certification program for use of the EXAcerbations of Chronic Pulmonary Disease Tool (EXACT).
Stentys appoints Stanislas Piot as Chief Financial Officer
PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--Stentys appoints new Chief Financial Officer
Systech and Marchesini Showcase Integrated Platform for Evolving Global Requirements
CRANBURY, N.J.--(BUSINESS WIRE)--Systech International, innovator of Packaging Execution Systems (PES), and Marchesini Group, leader in labeling technology, today announced that they are showcasing their integrated solution at the Marchesini demo center in France. The system, consisting of Systech Sentri and Marchesini’s BL400, enables manufacturers to meet vision inspection and labeling requirements such as French CIP13 and serialization requirements. Visitors will be able to see the system run
Long Term Data Presented at ESC 2010 Shed Further Light on the Benefit of the CYPHER® Sirolimus Drug-Eluting Stent Compared to the ENDEAVOR® Zotarolimus-Eluting Stent in Important High-Risk Subgroups
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Three new analyses of subgroups from the SORT OUT III study presented at the European Society of Cardiology (ESC) meeting in Stockholm, Sweden, provide additional detail on longer-term follow-up subgroup safety and efficacy outcomes in the SORT OUT III trial in three high-risk subgroups. These important data add detail to those already published in the March, 2010 issue of the Lancet on the clinical outcomes for the primary endpoint in the total population and
Rosetta Genomics to Host Second Quarter 2010 Conference Call on Wednesday, September 8, 2010
REHOVOT, Israel & PHILADELPHIA--(BUSINESS WIRE)--Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that the Company will release financial results for the three and six months ended June 30, 2010, after the market closes on Tuesday, September 7, 2010. Kenneth A. Berlin, President and Chief Executive Officer, and Limor Zur – Stoller, Vice President-Finance, will host a conference call for investors beginning at 10
Saint Barnabas Medical Center Implements ZOLL AutoPulse
CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of medical devices and related software solutions, announced today that Saint Barnabas Medical Center, one of the largest non-profit, non-sectarian hospitals in New Jersey, has installed the AutoPulse® Non-Invasive Cardiac Support Pump for resuscitative capabilities in the hospital’s emergency department. The AutoPulse is the only automated chest compression device that uses an easy-to-use, load-distrib
Orthovita to Present at the Stifel Nicolaus 2010 Healthcare Conference
MALVERN, Pa.--(BUSINESS WIRE)--Orthovita, Inc. (NASDAQ:VITA), an orthobiologics and biosurgery company, announced today that it will present at the Stifel Nicolaus 2010 Healthcare Conference in Boston. Antony Koblish, President and Chief Executive Officer of Orthovita, is scheduled to present on Wednesday, September 15, 2010, at 3:15 p.m. Eastern Time, at the Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116. A live webcast of the presentation will be available, and can be accessed for 3
BRINAVESS™ (vernakalant) for Infusion Approved in the European Union for Rapid Conversion of Recent Onset Atrial Fibrillation
WHITEHOUSE STATION, N.J. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Merck (known as MSD outside the United States and Canada) (NYSE:MRK) and Cardiome Pharma Corp. (NASDAQ: CRME/ TSX: COM) today announced that the intravenous (IV) formulation of BRINAVESS™ (vernakalant) has been granted marketing approval in the European Union (EU), Iceland and Norway for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults: for non-surgery patients with AF of seven days or
QuantRx Biomedical Consolidates Operations to Oregon
DOYLESTOWN, Pa.--(BUSINESS WIRE)--QuantRx® Biomedical Corporation (OTCBB:QTXB), an emerging leader in the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide point-of-care healthcare industry, today announced that it will be consolidating its operations in order to better serve its growing market demands. The operational consolidation will expand the Company’s presence in Portland, Oregon, and reflects a transition from